Ascentage Pharma to Present at Three Healthcare Conferences Feb 25–Mar 11
Ascentage Pharma management will present at Oppenheimer Life Sciences Conference on Feb 25 at 9:20am EST and host fireside chat at TD Cowen Health Care Conference on Mar 4 at 9:50am EST. Executives will hold one-on-one meetings at Jefferies Biotech on the Beach Summit on Mar 10 and 11, with webcasts via IR events page.
1. Conference Participation
Ascentage Pharma’s executive team is scheduled for three investor events: a presentation at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25 at 9:20am EST; a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 4 at 9:50am EST; and one-on-one meetings at the Jefferies Biotech on the Beach Summit on March 10 and 11.
2. Webcast and Meeting Access
All presentations and the fireside chat will be webcast live and available for replay on the Investor Relations events page. One-on-one meetings at the Jefferies summit will not be broadcast but details and summaries are expected to be provided through IR channels.
3. Company Pipeline and Investor Focus
These engagements offer Ascentage Pharma an opportunity to highlight its lead asset Olverembatinib—China’s first third-generation BCR-ABL1 inhibitor approved for multiple CML indications—and its novel Bcl-2 inhibitor Lisaftoclax, alongside ongoing global Phase III trials, aiming to deepen investor understanding of its oncology pipeline.